|
|||||
|
|
| 贝伐单克隆抗体对二乙基亚硝胺诱导的原发性肝癌大鼠的防治作用及其对肝癌组织VEGF表达的影响 | |
| 引用本文： | 张锋利,田华,吴洁琼. 贝伐单克隆抗体对二乙基亚硝胺诱导的原发性肝癌大鼠的防治作用及其对肝癌组织VEGF表达的影响[J]. 实用肝脏病杂志, 2017, 20(5): 563-566. DOI: 10.3969/j.issn.1672-5069.2017.05.014 |
| 作者姓名： | 张锋利 田华 吴洁琼 |
| 作者单位： | 712000 陕西省宝鸡市 陕西中医药大学第二附属医院消化内科（张锋利，吴洁琼） ；陕西中医药大学（田华） |
| 摘 要： | 目的 研究抗血管内皮生长因子（VEGF）单克隆抗体对二乙基亚硝胺（DEN）所致原发性肝癌大鼠的干预作用及其对肝组织VEGF表达的影响。方法 将30只SD 大鼠随机分为正常组、模型组和药物干预组。采用联合应用四氯化碳和DEN法制备原发性肝癌模型，并给予抗VEGF单克隆抗体腹腔注射干预，在正常组和模型组则给予等体积生理盐水注射。连续干预12 w。实验结束，取血和肝组织行相关检查，采用免疫组化法检测肝组织VEGF表达。结果 药物干预组大鼠肝质量、肝表面癌结节数，癌变率和肝脏指数分别为（17.51±2.53）g、（6.86±0.82）个、30%和（4.10±0.79），均明显低于模型组的【（23.71±3.01）、（21.91±2.75）、100.0%和（5.90±1.01），P<0.05】；与模型组比，药物干预组大鼠血清AST、ALT和TBIL水平分别为（101.58±19.83） IU/L、（241.52±36.58） IU/L和（62.93±3.03） μmol/L，均明显低于模型组（P<0.05）；病理学检查结果显示，与模型组比，药物干预组动物肝组织损伤明显减轻；免疫组化检测结果则显示，模型组、正常组和药物干预组VEGF相对表达量分别为（35.21±6.92）、（1.00±0.00）和（11.53±3.81），差异显著（P＜0.05）。结论 抗VEGF单克隆抗体对DEN诱导的原发性肝癌大鼠具有较好的抑瘤作用，而这种作用可能与其抑制了肝组织VEGF表达有关。 |
| 关 键 词： | 原发性肝癌 二乙基亚硝胺 抗血管内皮生长因子单克隆抗体 大鼠 |
| 收稿时间： | 2016-10-28 |
Inhibition of tumor growth and vascular endothelial growth factor expression of bevacizumab in rats with diethylnitrosamine-induced hepatic neoplasma |
|
| Zhang Fengli,Tian Hua,Wu Jieqiong.. Inhibition of tumor growth and vascular endothelial growth factor expression of bevacizumab in rats with diethylnitrosamine-induced hepatic neoplasma[J]. Journal of Clinical Hepatology, 2017, 20(5): 563-566. DOI: 10.3969/j.issn.1672-5069.2017.05.014 | |
| Authors: | Zhang Fengli Tian Hua Wu Jieqiong. |
| Affiliation: | Department of Gastroenterology，Second Affiliated Hospital，Shaanxi TCM University，Baoji 712000，Shaanxi Province |
| Abstract: | Objective To investigate the inhibition of tumor growth and vascular endothelial growth factor （VEGF） expression of bevacizumab in rats with diethylnitrosamine-induced hepatic neoplasma. Methods 30 SD rats were randomly divided into control，model and bevacizumab-intervened groups. The combination of tetrachloromethane and diethylnitrosamine（DEN） were used to establish liver cancer in rats. The bevacizumab or saline was given intraperitoneally for 12 weeks. The sera and liver tissues were obtained. The liver weights， surface carcinoma nodule numbers，canceration rates and liver index were detected. The VEGF expression was stained immunohistochemically. Results The liver weights，surface carcinoma nodule numbers，canceration rates and liver index were（17.51±2.53） g，（6.86±0.82），30% and（4.10±0.79） in the bevacizumab-intervened group， significantly lower than those in the model group[（23.71±3.01），（21.91±2.75），100.0% and（5.90±1.01）， respectively，P<0.05]；serum AST，ALT and TBIL levels were（101.58±19.83） IU/L，（241.52±36.58） IU/L and （62.93±3.03） μmol/L in the bevacizumab-intervened group，significantly lower than those in the model group（P<0.05）；Liver pathological examination showed that the liver injures，canceration and VEGF expression were alleviated in the bevacizumab-intervened group. Conclusions The application of Bevacizumab has a good inhibitory effect on DEN-induced canceration in rats，which warrants further study. |
| Keywords: | Hepatoma Diethylnitrosamine Bevacizumab Rats |
| 本文献已被 CNKI 等数据库收录！ | |
| 点击此处可从《实用肝脏病杂志》浏览原始摘要信息 | |
| 点击此处可从《实用肝脏病杂志》下载免费的PDF全文 | |